 The stock price of ChemoCentryx, a biopharmaceuticals company focused on orally-administered therapeutics to treat autoimmune diseases and inflammatory disorders, has seen a fall of 30 over the last month. The broader SP 500 Health Care index is down close to 10 over the last month due to. 